Through in silico methods, our findings suggest that PTX and HNK, when used in combination, exhibit increased binding affinity and bind to the same pocket when targeting MUC1, reinforcing the rationale for using dual-drug therapies in treating BrCa. This evidence concerns the gene MUC1 and invasive breast carcinoma.